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Abstract
Background:  Disease-management programmes including patient education have promoted
improvement in outcome for patients with heart failure. However, there is sparse evidence
concerning which component is essential for success, and very little is known regarding the validity
of methods or material used for the education.
Methods: Effects of standard information to heart failure patients given prior to discharge from
hospital were compared with additional education by an interactive program on all-cause
readmission or death within 6 months. As a secondary endpoint, patients' general knowledge of
heart failure and its treatment was tested after 2 months.
Results:  Two hundred and thirty patients were randomised to standard information (S) or
additional CD-ROM education (E). In (S) 52 % reached the endpoint vs. 49 % in (E). This difference
was not significant. Of those who completed the questionnaire (37 %), patients in (E) achieved
better knowledge and a marginally better outcome.
Conclusion: The lack of effect on the readmission rate could be due to an insufficient sample size
but might also indicate that in pharmacologically well-treated patients there is little room for
altering the course of the condition. As there was some indication that patients who knew more
about their condition might fare better, the place for intensive education and support of heart
failure patients has yet to be determined.
Background
The prevalence of heart failure has increased in the west-
ern world due to ageing of the general population and
improved survival of patients with acute coronary artery
disease [1]. Heart failure (HF) is a major concern for
health care providers due to increasing prevalence and ris-
ing health care costs [2]. The prognosis remains poor
despite improvement in survival due to treatment with
ACE-inhibitors and beta-receptor antagonists [3,4]. Heart
failure has a high rate of readmission and hospitalisation
[5]. Some readmissions have been ascribed to patients'
lack of compliance, insufficient knowledge about diet,
medication and symptoms of heart failure [6-8]. Educa-
tion of patients has become an important component in
order to increase the patients' self-care and compliance,
which might improve quality of life and reduce health
care costs [9-13].
Published: 24 June 2006
BMC Cardiovascular Disorders 2006, 6:30 doi:10.1186/1471-2261-6-30
Received: 28 March 2006
Accepted: 24 June 2006
This article is available from: http://www.biomedcentral.com/1471-2261/6/30
© 2006 Linné and Liedholm; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cardiovascular Disorders 2006, 6:30 http://www.biomedcentral.com/1471-2261/6/30
Page 2 of 10
(page number not for citation purposes)
In the European (ESC) guidelines for HF intense educa-
tion and counselling of patients (and other persons) is
recommended [14]. However, even if the recommenda-
tions are classified as Class I, the highest of three main
classes, the level of evidence for this action is grade C, the
lowest of three levels.
The same pattern appears in the American guidelines [15].
In that document, it is stated that observational studies
and randomized controlled trials have shown that dis-
ease-management programmes can reduce the frequency
of hospitalization and can improve quality of life and
functional status. However, it remains unclear which ele-
ments of disease-management programmes are crucial for
success.
When these programmes are viewed in detail, their com-
ponents and outcome differ. As it was commented in an
editorial article, "nothing of a class effect seem to exist"
[16]. However, among other things, patient education
(and self-management) is emphasised in the recommen-
dations set up by the American Heart Association [15].
Even if several systematic reviews of studies on strategies
for improvement of outcomes of HF patients after dis-
charge have been published, very little emphasis has been
put on methodological issues, e.g. methods of education
[17-20]. Many studies have shown that structured dis-
charge support, especially with multidisciplinary strate-
gies, can reduce readmission rates and in some cases even
mortality. Conflicting data have also been published, e.g.
in a recent nurse-directed telephonic HF management
programme, no measurable benefit of disease manage-
ment was found [21].
The information material in the majority of disease man-
agement programmes, as reviewed in the literature, only
exist as verbal and written material. Computer-based tools
seem to be relatively new [22]. In a recent review on the
crucial role of patient education in HF, it is stated that
education can still be improved by combining clinical
experience with new technologies, such as computer-
based education [23].
We have previously used an interactive CD-ROM program
for heart failure patients and have shown that it is possible
to increase patients' knowledge about heart failure and its
treatment [24,25]. Other investigators have evaluated the
user-friendliness of a similar CD-ROM based program
[26]. In our previous study a significant increase of knowl-
edge in the intervention group was shown [25]. However,
none of these studies examined the clinical outcome, e.g.
rate of readmission. We therefore performed a ran-
domised multi-centre study, in order to evaluate the
impact of added CD-ROM education on readmission rate
or death during 6 months.
Methods
This study aimed at education of HF patients concerning
a meaningful end-point. Patients were intended to be rep-
resentative of ordinary heart failure patients in mid- and
small-size general hospitals in Sweden. All hospitals were
community hospitals, and were supposed to follow the
same clinical (national) guidelines of care of heart failure
conditions. Efforts to include patients in the study
remained at the discretion of participating doctors and
nurses by screening consecutive in-patients treated for
heart failure. To decrease other bias in selection of
patients we included only clinics where no other trial in
cardiology was carried out at the same time. Locally
approved and standardised verbal information for heart
failure patients and the use of educational material,
including printed and audiovisual aids, were to be held
constant during the study. The management of the
patients was also restricted to a small number nurses in
each hospital, giving them control of the patient flow dur-
ing the study.
Randomisation
Patients were randomised to receive conventional infor-
mation/education or to additional interactive education
via CD-ROM at the time of hospital discharge. Patients
were randomised by telephone; hence, the sites had no
access to the randomisation list. Randomisation was
made by computer, and patients were stratified by clinic
and in three age groups < 65, 65–75, and > 75 years.
Inclusion and exclusion criteria
Criteria for heart failure was left ventricular ejection frac-
tion (LVEF) < 40 % at echocardiography or at least two of
the criteria pulmonary rates, peripheral oedema, a third
heart sound and signs of heart failure at chest X-ray.
Patients with somatic disease or physical handicap with
difficulties to communicate or handle the technical equip-
ment and patients with only little knowledge in Swedish
and patients with expected problems with compliance
due to alcohol/drug abuse or major psychiatric illness,
and participation in a trial, were excluded.
Procedures
During hospital stay, the patients who fulfilled the inclu-
sion criteria were invited to participate in the study.
Patients who accepted were randomised. Informed con-
sent was obtained in all cases.
Prior to discharge patients received the standard informa-
tion, which was given at the ward. Patients randomised to
the control group were then discharged to their usual care.BMC Cardiovascular Disorders 2006, 6:30 http://www.biomedcentral.com/1471-2261/6/30
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Patients randomised to the intervention group received
additional education by an interactive program on heart
failure, its symptoms and treatment. This program took
about 20–30 minutes. After discharge to their usual care,
the patients returned to the hospital after two weeks and
the CD program was repeated. The CD-program, which
was displayed on a TV set from a photo CD player, has
been described in detail before [24]. For the actual study
the program had been changed in one respect, i.e. more
explicit information on beta-blockers was given. The out-
line of the CD-program is shown in Table 1.
Primary endpoint
The primary, combined endpoint of the study was differ-
ence in rate of all cause readmission and death within 6
months after discharge.
Questionnaire
The patients' general knowledge of heart failure and its
treatment were tested with a questionnaire. The question-
naire was a slight modification of a version used in an ear-
lier study [25]. That version was developed from scratch as
there were no preceding studies in Sweden. It was based
on information given at the teaching sessions and the con-
tent of the CD-ROM used in that study.
The 16 questions in the questionnaire were as follows
(modified after translation).
1. Mention a drug used for treatment of heart failure that
can reduce swelling of the legs
2. What is the primary action of an ACE-inhibitor? Tick
one alternative
Contract vessels
Dilate vessels
Improve contraction of the heart
Decrease salt and water in the body
3. Mention a drug used for treatment of heart failure that
may improve your breathing
4. If your body weight goes up fast, what should you do
with the dose of your diuretic drug?
5. Which drug makes you pass urine more frequently?
6. Give a reason for taking an extra dose of your diuretic
drug
7. Do you measure how much you drink per day?
8. If you get sick and temporarily suffer from vomiting,
what should you do with the dose of your diuretic drug?
9. Which of the following drugs is important to take
exactly as prescribed? Tick one alternative
Nitroglycerin (e.g. Nitromex)
Table 1: Outline of content of the CD. In short – after choosing either of the main issues, as shown in the second row of the table, the 
patient follows the items presented in the column below. If picking a wrong alternative in response to a question, the next frame tells 
that it was wrong but does also mention the right answer. Then the question automatically reappears until the right answer is chosen; 
otherwise the program will not proceed beyond that part. After having finished one of the two main issues, the program automatically 
turns to the remaining issue. Figures in brackets are number of frames of the program.
Heart failure
The purpose of the CD (1)
1. The disease 2. The treatment
General (2) Diuretics (4 special + 1 general)
Tiredness (1) Fluid intake (1 special + 4 general)
Dyspnoea (1) - Question (diuretics): right (1), wrong (2)
Fluid accumulation (3) - Question (fluid intake): right (1), wrong (2)
End of first part (1) Use of diuretics – conclusion (1)
Treatment of symptoms (1) ACE-inhibitors (4)
Aetiology (1) - Question: right (1), wrong (2)
Deterioration (1) Digitalis (3)
Symptoms and signs of deterioration (2) - Question: right (1), wrong (2)
Reasons for deterioration Beta blockers (4)
- Pharmacological reasons (1) - Question: right (1), wrong (2)
- Other conditions (1) Reminder on use of diuretics (1)
Course of deterioration End of this session (1)
End of this session (1)
Ending message (after watching the whole CD)BMC Cardiovascular Disorders 2006, 6:30 http://www.biomedcentral.com/1471-2261/6/30
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Digitalis (e.g. Lanacrist/Digoxin)
Diuretic (e.g. Impugan/Furix/Furosemid)
10. Which side-effect is likely to get from an ACE-inhibi-
tor? Tick one alternative
Dizziness
Loss of potassium and magnesium
Upset stomach
11. At most, how much are you advised to drink daily?
12. If you get sick and temporarily suffer from diarrhoea,
what should you do with the dose of your diuretic drug?
13. If your legs get swollen or the swelling increases, what
should you do with the dose of your diuretic drug?
14. If you get a fever, what should you do with the dose of
your diuretic drug?
15. Which of the following drugs may cause a patient to
cough? Tick one alternative
Diuretic (e.g. Impugan/Furix/Furosemid)
Digitalis (e.g. Lanacrist/Digoxin)
ACE-inhibitor (e.g. Renitec/Triatec/Zestril/Capoten)
16. Which of the following drugs may cause an upset
stomach and increase the risk of bleeding, e.g. if you have
to have a surgical operation. Tick one alternative
Digitalis (e.g. Lanacrist/Digoxin)
Diuretic (e.g. Impugan/Furix/Furosemid)
Aspirin (e.g. Trombyl)
The questionnaire was sent by regular mail to the patients
8 weeks after randomisation. Returned questionnaires
were kept sealed until the whole study was closed. A sec-
retary, unrelated to study participants and the people
responsible for the study, made a formal classification of
the answers. Allocation of patients and the outcome of the
study were masked.
A computerised patient administrative system, PAS, was
used to verify all-cause readmissions and deaths within 6
months from discharge. Reasons for readmission or sub-
sequent readmissions were not accounted for.
Ethics
The investigation conforms with the principles outlined
in the Declaration of Helsinki (Br Med J 1964, ii:177). The
study was approved by the Committee on Research Ethics
of the Lund University, Sweden.
Statistical analyses
In an ecological study the all-cause readmission rate and
deaths were shown to be 53 % of heart failure patients
within 6 months [5]. At the planning of our study, there
was no evidence from randomised studies using educa-
tional methods to base a reliable calculation of study size
on. To increase the knowledge of a reasonable sample size
for our study, we searched for useful data from published
studies showing significant results of the intervention.
In a randomised study of intervention by a multidiscipli-
nary team to prevent readmission in heart failure patients,
a reduction from 67 % readmission rate in the control
group to 37 % in the intervention group was shown after
90 days [12]. A post hoc calculation of power and sample
size gave a power of 99 % from the actual sample size of
282 patients (nQuery Advisor® 5.0). A study with 80 %
power would only need 100 patients.
In another study, including a clinical pharmacist in the
team, the sample size of the study was 181 patients in
total [27]. There were 4 cases of all-cause mortality and
nonfatal heart failure in the intervention group (n = 90),
and 16 cases in the control group (n = 91) during 6
months follow-up. A post hoc calculation of power gave a
power of 81 % from the actual sample size. A study with
80 % power would marginally decrease the size of the
sample to 175 patients. In neither of these studies an à pri-
ori calculation of power was presented.
To detect a 20 % difference in outcome between two
groups with 80 % power and a significance level of 5 %
(two-sided), a total sample size of 206 patients would be
required (nQuery Advisor® 5.0) in our study.
For conventional parametric and non-parametric statisti-
cal calculations we used the statistical software StatsDirect
Version 2,3,8. Tests for normality were included. For cal-
culation of survival the Peto & Peto Wilcoxon test in the
same software was used.
Results
Much effort was spent to include clinics in this study,
which was funded by non-commercial funds. Nineteen
clinics were approached, but four major clinics were pre-
occupied with other clinical studies. The final study
included clinics at the following hospitals (in alphabetical
order) in Sweden: Eskilstuna, Helsingborg, Kalmar, Karl-
skoga, Karlskrona, Karlstad, Kristianstad, Ljungby,BMC Cardiovascular Disorders 2006, 6:30 http://www.biomedcentral.com/1471-2261/6/30
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Nyköping, Trelleborg, Visby, Växjö, and Ystad. Two other
clinics started the study but due to reorganization and
introduction of new patient caring routines, they dropped
out of the study. No patients from these clinics were
included in the analysis. The number of screened patients
per clinic ranged from 10 to 96. The first patient was ran-
domised in February 1998 and the last patient in July
2002.
Patient flow
The patient flow in the study is shown in figure 1.
Patients' characteristics
Two hundred and thirty patients were randomised (108
controls and 122 interventions).
Patient characteristics at randomisation are presented in
Table 2. All patient characteristics were similar except
from the use of digitalis and aspirin at discharge from hos-
pital.
Outcome measures
Primary endpoint
The difference between the two groups was not signifi-
cant. Mortality rate was low – only one patient in the con-
trol group and 4 patients in the intervention group died
during the study. In the control group 55/106 (52 %)
patients reached the combined end-point, in the interven-
tion group 58/118 (49 %) patients. The Peto & Peto Wil-
coxon test for survival was not significant, p = 0.592.
Figure 2 shows the Kaplan-Meier curves.
Questionnaire
Only 82 of 224 patients, who finished the study (37 %),
completed the questionnaire. Patients in the intervention
group (n = 43) reached a significantly higher score (mean
score 10.1 points range 4–15) than the control group (n =
39), (mean score 7.7 points, range 2–14), p = 0.004. No
significant differences were seen between the groups
regarding sex, age or use of drugs documented for survival
in heart failure (ACE-inhibitors, beta blockers and
spironolactone).
A comparison of data between those who completed or
did not complete the questionnaire showed no difference
regarding sex, age or use of documented drugs. Analysis of
primary endpoint in the sub-group who completed the
questionnaire showed a borderline significant difference
between the intervention group and the control group,
Peto & Peto Wilcoxon test p = 0.05039. Figure 3 shows the
Kaplan-Meier curves.
Discussion
This study did not show any effect on the primary end-
point of adding an interactive, CD-based education to the
regular education of and information to previously hospi-
talised patients with heart failure. In a study with a "nega-
tive" result, one can always discuss if this is due to a type
II error, i.e. the study had been underpowered. In an effort
to shed light on this item, we simulated a bigger study by
adding results from our previous RCT of similar design
and same duration [25]. That study was only designed to
test the impact of the CD program education on knowl-
edge. Data about readmission and death from all partici-
pants (n = 108) were extracted from the files and added to
the actual study. However, even after this addition, no
effect on the primary end-point was detected.
Could it then be that all necessary knowledge for under-
standing and self-management of the condition already
had been transferred to the patients and that additional
education by the CD-program, even if it was repeated, was
redundant? This view is not supported by the data from
completed questionnaires in the actual study, where a sig-
nificantly higher score was attained in the CD-educated
group. However, the number of completed questionnaires
was low, in spite of our ambition to follow the same man-
agement as was expressed in a recent Cochrane review
[28].
The target population was representative of ordinary HF
patients treated in rural and urban hospitals. The quality
of the baseline care as expressed by the use of ACE-inhib-
itors (80 %) was high, probably a result of the impact of
National Programmes in cardiology in Sweden (The
Swedish National Board of Health and Welfare's Guide-
lines for Cardiac Care, latest version published in 2004).
The management of patients in the study consisted of gen-
eral nurse-based methods of care for HF patients, e.g. edu-
cation, enhancing self-care, and monitoring of drug
treatment.
One hundred and thirteen eligible patients refused to par-
ticipate. In this trial, patients had to come twice to the CD-
based education, first as in-patients, the second time at
approximately 2 weeks after discharge. Returning to the
hospital may have discouraged some patients to partici-
pate, in this manner recruiting less sick patients.
With regard to study planning and power for sample size
calculation, two studies of interest have been published
after the start of our own [29,30]. In the first study it was
stated that with 80 % power the sample size should
include 164 patients to detect a 23 % difference in mortal-
ity and hospital readmission due to heart failure after one
year. A 26 % difference was detected after one year. In the
second study (n = 280) no power calculation was given,
but this study has some similarities with our own. Both
included in-patients, were of the same size, drug treat-
ment was in many aspects similar, and patients were edu-BMC Cardiovascular Disorders 2006, 6:30 http://www.biomedcentral.com/1471-2261/6/30
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Patient distribution in the trial Figure 1
Patient distribution in the trial.
No heart failure - 161 
Screened for eligibility - 596 
HF not fully confirmed - 18 
Excluded - 187 
- refused - 113 
- other serious disease – 36 
- psychic illness, dementia etc – 15 
- other reasons (visual acuity etc) – 23 
Eligible - 435 
Randomised to control - 108  Randomised to intervention - 122 
Finished study – 118 
- reached endpoint - 58  
  - readmission – 54 
- deaths - 4
Finished study – 106 
- reached endoint – 55  
   - readmission – 54 
   - deaths - 1 
Refused further 
participation - 2 
Refused further 
participation - 4 BMC Cardiovascular Disorders 2006, 6:30 http://www.biomedcentral.com/1471-2261/6/30
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cated before discharge from the hospital. The studies were
different in other aspects. Their patients were younger
(age difference 10 years) and seem to have had a more
serious disease. However, readmission rate at 6 months
was of the same magnitude and no statistical difference
was detected.
Table 2: Patients' characteristics at randomisation. If not otherwise stated, data is arithmetic mean and standard deviation.
Patient characteristics Controls Intervention
Number of patients 108 122
Sex (F/M) 26/82 42/80
Age, years (range) 70.8 (41–88) 70.3 (34–89)
Weight, kg 81.8 (20.2) 77.6 (17.3)
Height, cm 173.6 (8.2) 172.0 (9.6)
Treatment at randomisation
Diuretics, n (%) 95 (90) 110 (90)
ACE-inhibitors, n (%) 85 (79) 99 (81)
Beta-blockers, n (%) 46 (43) 67 (55)
Spironolactone, n (%) 24 (22) 22 (18)
Digitalis, n (%) 28 (26) 54 (44)*
Aspirin, n (%) 36 (33) 60 (49)*
Blood chemistry
Creatinine, μmol/L 120.1 (43.0) 111.4 (42.4)
Glucose, mmol/L (median, inter-quartile range) 5.5 (4.8–7.2) 5.65 (4.7–6.7)
Potassium, mmol/L 4.0 (0.4) 4.0 (0.4)
* Significant differences between treatment groups (Fisher's exact test), p = 0.004 and 0.016 respectively.
Time to first event in the intervention group (dotted line) and the control group (straight line) Figure 2
Time to first event in the intervention group (dotted line) and the control group (straight line).
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In a recent (n = 462) study lasting one year, there was no
difference regarding the primary combined endpoint
(death, rehospitalisation or emergency department visit
for cardiac causes or any cause) between the intervention
and the control group [21]. At 6 months, the proportion
of patients reaching the end-point was estimated to about
42 % in the intervention and 50 % in the control group,
as judged from the survival curves published in the report.
We obtained quite similar figures. In the comments to this
study, the accompanying Editorial discussed the (nega-
tive) outcome of this and three earlier trials [31]. Three
items were recognised as factors that could account for the
divergent outcomes of similar studies: a) the target popu-
lation, b) the quality of usual care, and c) the design of the
management programme. Difficulties with self-manage-
ment, low self-efficacy, social deprivation, and chaotic use
of health care system were appointed to be more useful
characteristics than traditional disease characteristics for
identification of patients responsible to the management
programmes.
Even if it was a post-hoc subgroup analysis based on small
numbers, the better result regarding readmissions in those
who completed questionnaires, gives hope that better
knowledge by education and a subsequently better self-
management may still work at a larger scale. This has to be
tested in a formal trial where both variables are tested at
the same time, which was not the case in our study. To
prove that this method also may have an impact on the
death rate remains, in our opinion, a much more difficult
task.
Different studies continue to give conflicting results, and
a full identification of prognostic factors still has to be
determined. At this moment, the optimal structure and
role of education and self-management programs of HF
patients cannot be fully settled.
Conclusion
Additional education of HF patients with an interactive
program had no effect on readmission rate or death
within 6 months after discharge. The lack of effect may be
Time to first event of those in the intervention group (dotted line) and the control group (straight line) who answered the  questionnaire Figure 3
Time to first event of those in the intervention group (dotted line) and the control group (straight line) who answered the 
questionnaire.
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due to an insufficient sample size of the study. It might
also indicate that in pharmacologically well treated
patients there is relatively little room left for altering the
natural course of the condition. However, as there was
some indication that patients who knew more about their
condition might fare better, the place for intensive educa-
tion and support of HF patients has yet to be determined.
The formal, controlled testing of validated methods for
patient education should be encouraged. The variables
should not only be knowledge but should also include
patient behaviour (e.g. self-management) and a clinical
outcome, such as tested in our study. Our study has made
an input to the discussion of calculation of statistical
power for similar studies, as was lacking at the onset.
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